Search Results
Apr 09, 2026, 07:00 ET Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.
More news about: Compugen Ltd.
Apr 09, 2026, 07:00 ET OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
novel and well validated targets across oncology and immunological diseases. Among them, AI-081 is a fully owned bispecific antibody candidate targeting PD-1 and VEGF. ONC-841 is a first-in-class anti-SIGLEC 10 antibody currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative
More news about: OncoC4
Apr 08, 2026, 08:30 ET Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
type of lung cancer and remains a leading cause of cancer-related deaths worldwide. For patients with driver-negative tumors that express high levels of PD-L1 (tumor proportion score ≥50%), first-line treatment options include immunotherapy alone or, in cases where the disease is considered more aggressive,
More news about: Caris Life Sciences
Apr 07, 2026, 15:05 ET Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.Phanes is conducting clinical trials with spevatamig in multiple oncology indications, including a Phase 2 study evaluating
More news about: Phanes Therapeutics
Apr 07, 2026, 09:00 ET Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China
Administration (FDA). The ongoing first-in-human Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of DXP-106 in patients with advanced solid tumors."Dosing of the first patient in our Phase I trial represents
More news about: Singlomics Biopharmaceuticals
Apr 07, 2026, 09:00 ET Motorola unveils the moto g stylus - 2026 and moto pad - 2026, powering seamless creativity across screens
Available with 5G service plan and 5G network coverage; available only in select areas. See carrier for details.Maximum 20W charging requires a PD 3.0 protocol compatible Motorola TurboPower™ charger rated above 20W (sold separately). Chargers exceeding 20W will not increase charging speeds beyond
More news about: Motorola Mobility, Inc
Apr 07, 2026, 08:00 ET New randomized controlled trial shows professional development aligned with Teaching Strategies' ecosystem improves teacher retention and child outcomes
participation in training and use of digital tools were associated with stronger child outcomes across various domains.Teachers receiving the PD reported higher levels of professional accomplishment and lower emotional exhaustion. Qualitative findings indicated that educators viewed the curriculum
More news about: National Institute for Early Education Research (NIEER)
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
combination with anlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who progressed after prior PD-(L)1 inhibitor-based therapy. Cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy, having received marketing approval
More news about: Akeso, Inc.
Apr 06, 2026, 14:52 ET La Alianza Nacional para la Salud Hispana y la Parkinson's Foundation se unen para generar conciencia sobre el Mes de la Concientización sobre el Parkinson 2026
de confianza obtenidas de Parkinson.org. Para apoyo personalizado, las personas pueden llamar a la Línea de Ayuda de la Fundación, llamando al 1-800-4PD-INFO (1-800-473-4636), opción 3 para español, para hablar con un especialista en información y recibir respuestas en inglés y español. La Línea Nacional
More news about: National Alliance for Hispanic Health
Apr 06, 2026, 13:42 ET The National Alliance for Hispanic Health and the Parkinson's Foundation Join Together to Raise Awareness for Parkinson's Awareness Month 2026
answers to a variety of PD questions, including using its new AI-powered chat tool, Ask PAM (Parkinson's Assistance Messenger), which delivers trusted answers sourced from Parkinson.org. For personalized support, individuals can call the Foundation's Helpline at 1-800-4PD-INFO (1-800-473-4636) to
More news about: National Alliance for Hispanic Health
Apr 06, 2026, 09:00 ET Abbott recebe aprovação regulatória no Brasil de serplulimabe, novo medicamento biológico para o tratamento de câncer de pulmão de pequenas células com doença extensa, oferecendo uma nova alternativa para pacientes
tempo juntos, em um momento muito importante."Mecanismo de ação do PD-1Serplulimabe atua removendo um "freio" nas células do sistema imunológico, uma proteína chamada PD-1.1,12 Quando ativado, o PD-1 envia sinais às células do sistema imunológico para reduzir ou interromper
More news about: Abbott
Apr 03, 2026, 15:41 ET Leading Parkinson's Organizations Urge Congress to Preserve Progress and Strengthen Parkinson's Research Funding at the National Institutes of Health
Parkinson Disease Association (APDA) is a nonprofit organization dedicated to fighting Parkinson's disease (PD) by providing the support, education, research, and community that helps everyone impacted by PD live life to the fullest. Through a nationwide grassroots network of Chapters and Information &
More news about: The Michael J. Fox Foundation for Parkinson's Research
Apr 03, 2026, 10:44 ET Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform
covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway
More news about: Westlake University
Apr 02, 2026, 12:00 ET Greenland Mines Subsidiary Major Precious Greenland A/S Joins Greenland Business Association
relationsFor Greenland Mines, this step complements its technical and environmental work, underlining the Company's commitment to building its Skaergaard Au-Pd-Pt and critical metal project in close cooperation with Greenlandic stakeholders and institutions.Supporting long‑term value
More news about: Greenland Mines Ltd
Apr 01, 2026, 05:27 ET American Parkinson Disease Association Kicks Off Awareness Month with Launch of New Public Service Announcement
Love" campaign aims to educate the public about PD – challenging outdated stereotypes about who it affects and what it looks like – and provide inspiration and hope to those living with the disease. Most importantly, APDA wants everyone impacted by PD to know that they are not alone and that the organization
More news about: American Parkinson Disease Association, Inc.
Mar 31, 2026, 22:02 ET Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
with FGF19 overexpression.In addition to monotherapy, Abbisko Therapeutics is exploring irpagratinib in combination with atezolizumab, an anti-PD-L1 antibody manufactured by F. Hoffmann-La Roche and Roche (China), in a Phase II study. At the the 2025 ESMO GI Congress, Abbisko presented clinical
More news about: Abbisko
Mar 31, 2026, 08:56 ET Breaking the PCR-Only Barrier: Dual 510(k) Clearance and CLIA-Waiver Establish FINDER as the First Molecular Point-of-Care Platform with Multifunctional Capabilities
built for real-world near-patient testing.FINDER also extends beyond molecular. Baebies previously received FDA 510(k) clearance for the FINDER G6PD Test on an earlier version of the platform, and its FINDER Anti-Factor Xa Test received FDA Breakthrough Device Designation as the first point-of-care
More news about: Baebies Inc.
Mar 31, 2026, 08:55 ET Parkinson's Foundation Launches "Find Real Answers" Campaign for Parkinson's Awareness Month this April
reliable information, we want to help people understand PD and connect with the tools they need to live better."This April, the Foundation encourages people to explore multiple ways to get answers to a variety of PD questions, including using its new AI-powered chat tool,
More news about: Parkinson's Foundation
Mar 31, 2026, 08:55 ET La Parkinson's Foundation lanza la campaña "Encuentre respuestas reales" para el Mes de la Concientización sobre el Parkinson este abril
Línea de Ayuda de la Fundación, llamando al 1-800-4PD-INFO (1-800-473-4636), opción 3 para español, para hablar con un especialista en información y recibir respuestas en inglés y español.La Fundación
More news about: Parkinson's Foundation
Mar 31, 2026, 08:54 ET Parkinson's Foundation Launches "Find Real Answers" Campaign for Parkinson's Awareness Month this April
source for reliable information, we want to help people understand PD and connect with the tools they need to live better."This April, the Foundation encourages people to explore multiple ways to get answers to a variety of PD questions, including using its new AI-powered chat tool,
More news about: Parkinson's Foundation
Mar 31, 2026, 08:13 ET 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
705 (Anti-PD-1/HER2 BsAb): Currently in Phase II clinical development for HER2-positive advanced solid tumors, it is the only candidate in China actively advancing clinical trials for this target, boasting significant differentiated advantages.706 (Anti-PD-1/PD-L1 BsAb):
More news about: 3SBio Inc.
Mar 31, 2026, 05:40 ET Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as a first-line treatment for patients with PD-L1–positive non-small cell lung cancer (NSCLC). In the primary analyses of HARMONi-2, ivonescimab
More news about: Akeso, Inc.
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
Positive efficacy and safety data have been observed in the monotherapy trial targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, colorectal cancer (CRC), neuroendocrine neoplasm (NEN) and hepatocellular carcinoma (HCC).In October 2025, the Company
More news about: Harbour BioMed
Mar 30, 2026, 09:00 ET Aurzen Unveils the Portable EAZZE D1 air, Delivering Smart TV Simplicity with Built-In Streaming and USB-C Power
A recessed USB-C port with 65W PD support allows D1 air to run from common laptop chargers or portable power banks, making it easy to move from room to room or take entertainment outdoors.
More news about: Aurzen Official
Mar 30, 2026, 09:00 ET Aurzen Unveils the Portable EAZZE D1 air, Delivering Smart TV Simplicity with Built-In Streaming and USB-C Power
A recessed USB-C port with 65W PD support allows D1 air to run from common laptop chargers or portable power banks, making it easy to move from room to room or take entertainment outdoors.
More news about: Aurzen Official